6533b7d5fe1ef96bd1263ea8
RESEARCH PRODUCT
Wild-type JAK2 secondary acute erythroleukemia developing after JAK2-V617F-mutated primary myelofibrosis.
Daniel B. LipkaCharles James KirkpatrickErik SpringerAndreas Kreftsubject
business.industryWild typeHematologyGeneral MedicineAnagrelideJanus Kinase 2Middle Agedmedicine.diseaseCell Transformation NeoplasticFatal OutcomePrimary Myelofibrosishemic and lymphatic diseasesMutation (genetic algorithm)Female patientCancer researchMedicineAcute erythroleukemiaHumansFemaleLeukemia Erythroblastic AcutebusinessMyelofibrosisJAK2 V617Fmedicine.drugdescription
A 54-year-old female patient developed acute erythroleukemia after an 8-year course of primary myelofibrosis. The latter harbors the JAK2-V617F mutation and was treated with hydroxyurea and anagrelide. A bone marrow trephine biopsy disclosed 2 morphologically distinct areas of chronic primary myelofibrosis and acute erythroleukemia. Microdissection and a separate molecular pathological analysis was performed. Although the activating JAK2-V617F mutation was not maintained in blasts of acute erythroleukemia, it was detectable in the chronic phase of primary myelofibrosis, indicating that this mutation did not play a role in the leukemic transformation of erythroid cells.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2009-05-12 | Acta haematologica |